U.S. markets open in 8 hours 41 minutes
  • S&P Futures

    3,760.50
    -5.00 (-0.13%)
     
  • Dow Futures

    30,842.00
    -36.00 (-0.12%)
     
  • Nasdaq Futures

    12,432.50
    -22.50 (-0.18%)
     
  • Russell 2000 Futures

    2,139.20
    -5.30 (-0.25%)
     
  • Crude Oil

    64.39
    +0.56 (+0.88%)
     
  • Gold

    1,692.50
    -8.20 (-0.48%)
     
  • Silver

    25.29
    -0.17 (-0.67%)
     
  • EUR/USD

    1.1965
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.5500
    -1.5500 (-100.00%)
     
  • Vix

    28.57
    -26.67 (-100.00%)
     
  • GBP/USD

    1.3887
    -0.0007 (-0.05%)
     
  • USD/JPY

    108.0840
    +0.1080 (+0.10%)
     
  • BTC-USD

    47,206.36
    -2,149.67 (-4.36%)
     
  • CMC Crypto 200

    942.66
    -44.55 (-4.51%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,625.13
    -304.98 (-1.05%)
     

Recap: Masimo Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Masimo (NASDAQ:MASI) fell  in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 7.69% year over year to $0.98, which beat the estimate of $0.86.

Revenue of $295,054,000 rose by 19.21% from the same period last year, which beat the estimate of $287,450,000.

Guidance

Masimo Sees FY21 Adj. EPS $3.80 vs $3.84 Est., Sales $1.2B vs $1.19B Est.

Details Of The Call

Date: Feb 23, 2021

Time: 04:30 PM

View more earnings on MASI

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.masimo.com%2F&eventid=2943410&sessionid=1&key=6CFCE0591A3E7510420A642FEC6EA3AF&regTag=&V2=false&sourcepage=register

Technicals

52-week high: $284.86

Company's 52-week low was at $143.90

Price action over last quarter: Up 4.82%

Company Profile

Masimo is an Irvine, California-based medical device business that focuses on noninvasive patient monitoring. It began by developing superior signal processing algorithms to measure blood oxygenation levels through pulse oximetry and has expanded this expertise into a wide range of measurements and applications. The company generates revenue globally, with the United States the largest market (68% of 2019 sales), followed by Europe, the Middle East, and Africa (20%), Asia and Australia (9%), and North and South America excluding the U.S. (3%).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.